Developing both prophylactic 
and therapeutic effective 
countermeasures

Crimean Congo Haemorrhagic Fever 
Vaccine & Immunotherapy

The CCHFVACIM project aims to address the serious public health threat posed by Crimean Congo Haemorrhagic Fever Virus (CCHFV), a tick-borne zoonotic virus that causes fatal epidemics in humans. This is one of the most threatening vector-borne pathogens, widely distributed, including on the European continent. Currently, there are no preventive or effective therapeutic measures available against CCHFV, which is listed as a key priority in the WHO’s R&D Blueprint list of infectious agents with epidemic or pandemic potential.

Deep structural biology studies on viral glycoproteins and investigation of the immunogenicity of the viral antigens will be combined with optimisation of a mRNA vaccine candidate against the virus and characterisation of the resulting protective immunity, as well as with the development of immuno-therapeutic monoclonal antibodies (mAbs) based on CCHFV’s antigenic targets.


Numbers

0

partners

0

countries

0

years EU-funded

project

0M

€

News

  • New Publication!

    Immunogenicity of NSDV GP38 and the Role of Furin in Glycoprotein Processing We are proud to highlight a new peer-reviewed publication by Kerstin Fischer and colleagues at the Friedrich-Loeffler-Institut (FLI), supported by the CCHFVacim project and funded by the European Health and Digital Executive Agency (HaDEA). 🔬 The study explores the presence and immunogenicity of the GP38 glycoprotein in sheep…

  • Watch Ali MIRAZIMI

    Why is it so important to develop medical counter measures against CCHF virus ? Listen to Ali Mirazimi’s answer in Thessaloniki (or read it: subtitled with Kapwing).

  • Annual Meeting in Thessaloniki

    What an incredible meeting in Thessaloniki!It was a real pleasure seeing the fantastic progress of the CCHFVACIM project. A huge congratulations to the entire team! We’re excited to share that the data collected will be key to advancing a vaccine candidate to Phase I trials. Stay tuned for upcoming publications and further milestones—this is just…